High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study

Biomedical Chromatography

Volumn 22, Issue 11, 2008, Pages 1213-1224

  Patel, Bhavin N ^a,b   Sharma, Naveen ^b   Sanyal, Mallika ^c   Prasad, Arpana ^b   Shrivastav, Pranav S ^a  

^a GUJARAT UNIVERSITY   (India)

^b BA Research India Limited   (India)

^c ST XAVIER S COLLEGE   (India)

Author keywords

6 methoxy 2 naphthylacetic acid; Bioequivalence; Human plasma; LC MS MS; Multiple reaction monitoring

Indexed keywords

LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; PHASE SEPARATION; PLASMA (HUMAN);

6-METHOXY-2-NAPHTHYLACETIC ACID; ACTIVE METABOLITES; BIOEQUIVALENCE; BIOEQUIVALENCE STUDY; HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS-MS; LC.MS/MS; MULTIPLE REACTION MONITORING; NABUMETONE;

POSITIVE IONS;

6 METHOXY 2 NAPHTHYLACETIC ACID; DRUG METABOLITE; NABUMETONE; PROPRANOLOL;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN EXPERIMENT; INDIAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS;

EID: 65949121371     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1047     Document Type: Article

References (20)

1. Bourke B, Under NA and Thawley AR. An investigation into the penetration of nabumetone and its metabolites into synovial fluid in patients with rheumatoid arthritis. Royal Society of Medicine International Congress and Symposium Series 1985; 69: 31-35.
2. Can NO, Tuncel M and Aboul-Enein HY. Determination of nabumetone in pharmaceutical formulation by flow injection analysis (FIA) with UV-detection. Pharmazie 2003; 58: 22-24.
3. Dahl SL. Nabumetone: a 'nonacidic' nonsteroidal anti-inflammatory drug. The Annals of Pharmacotherapy 1993; 27: 456-463.
4. Davies NM. Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition. Clinical Pharmacokinetics 1997; 33: 404-416.
5. FDA. Guidance for Industry: Bioavailability Studies for Orally Administered Drug- Products-General Considerations. US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research, 2000.
6. FDA. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research, Centre for Veterinary Medicine, 2001.
7. Friedel HA, Langtry HD and Buckley MM. Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs 1993; 45: 131-136.
8. Gonzalo-Garijo MA, Cordobes-Duran C, Lamilla-Yerga AM and Moreno-Gaston I. Severe immediate reaction to nabumetone. Journal of Investigational Allergology and Clinical Immunology 2007; 17: 274-276.
9. Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung KA and Ekbom A. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 2004; 64: 2315-2343.
10. Helfgott SM. Nabumetone: a clinical appraisal. Seminars in Arthritis and Rheumatism 1994; 23: 341-346.
11. Jager AD, Hundt HK, Hundt AF, Swart KJ, Knight M and Roberts J. Extractionless determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 2000; 740: 247-251.
12. Kobylinska K, Barlinska M and Kobylinska M. Analysis of nabumetone in human plasma by HPLC. Application to single dose pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis 2003; 32: 323-328.
13. Mikami E, Goto T, Ohno T, Matsumoto H and Nishida M. Simultaneous analysis of naproxen, nabumetone and its major metabolite 6-methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 2000; 23: 917-925.
14. Nobilis M, Kopecky J, Kvetina J, Svoboda Z, Pour M, Kunes J, Holcapek M and Kolarova L. Comparative biotransformation and disposition of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection. Journal of Pharmaceutical and Biomedical Analysis 2003; 32: 641-656.
15. Nobilis M, Holcapek M, Kolarova L, Kopecky J, Kunes M, Svoboda Z and Kvetina J. Identification and determination of phase II nabumetone metabolites by high-performance liquid chromatography with photodiode array and mass spectrometric detection. Journal of Chromatography A 2004; 1031: 229-236.
16. Qin Y, Zou Y, Liang M, Huang Y and Yu Q. Determination of 6- methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by HPLC. Hua Xi Yi Ke Da Xue Xue Bao 1999; 30: 452-454.
17. Rao RN, Meena S, Nagaraju D and Rao AR. Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids. Biomedical Chromatography 2005; 19: 362-368.
18. Ray JE and Day RO. High-performance liquid chromatographic determination of a new anti-inflammatory agent, nabumetone, and its major metabolite in plasma using fluorimetric detection. Journal of Chromatography 1984; 336: 234-238.
19. Schrader HW, Buscher G, Dierdorf D, Mugge H and Wolf D. Nabumetone - a novel anti-inflammatory drug: the influence of food, milk, antacids and analgesics on bioavailability of single oral doses. International Journal of Clinical Pharmacology, Therapy and Toxicology 1983; 21: 311-321.
20. Sheen JF and Her GR. Application of pentafluorophenyl hydrazine derivatives to the analysis of nabumetone and testosterone in human plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. Analytical and Bioanalytical Chemistry 2004; 380: 891-897.